Victor Li, Chairman of CKLIFE SCIENCES (00775.HK)  -0.030 (-3.488%)   , was asked about his views on the company's prospects after the shareholders' meeting. He remarked that biotech research is a high-return/ high-risk industry. If successful, the value of a single product could excel many listed companies in infrastructure or even real estate fields, while if unsuccessful, there is nothing to say.

Therefore, Li believed that there is no reason to invest in the biotech industry, if one buys stocks purely for dividends; but if one has a comprehensive portfolio, allocating a portion of funds to such high-stakes investments is correct.

When asked whether he is weighing a ring-fence of the biopharmaceutical division and listing it under Chapter 18A in Hong Kong, Li replied that he will continue to evaluate strategic opportunities to enhance shareholder value and optimize business structure.

As for whether to conduct equity placements, issue convertible bonds, or sell non-core assets to raise funds for research, Li stated that the company will allocate capital prudently, but currently has no news to announce regarding fundraising plans.

He also mentioned that the healthcare products business and agriculture-related business are paramount to the company, with operational performance continuing to be promising and generating stable cash flow, providing essential resources for research and development.
(HK stocks quote is delayed for at least 15 mins.)